Wolfgang Miesbach: Attitudes Towards Gene Therapy for Severe Haemophilia in Germany
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Therapeutic Advances in Hematology, adding:
”Delighted to share our new paper on attitudes towards gene therapy in people with severe haemophilia in Germany.
Using a questionnaire originally developed and applied in an Italian haemophilia population, we surveyed 69 men with severe haemophilia A or B in Germany to assess knowledge, attitudes, risk tolerance, and decision-making preferences regarding gene therapy.
- Attitudes: Most participants were satisfied with their current prophylaxis, and accordingly 59% expressed a predominantly rejective attitude towards gene therapy. This underlines that, for many, gene therapy is perceived as an optional intervention.
- Knowledge and expectations: About half of participants could not answer more than half of the knowledge questions correctly, showing limited and often superficial knowledge about gene therapy.
- Safety: Long-term safety concerns, particularly fear of cancer and liver toxicity, were a major driver of negative attitudes.
- Bleed burden: People with an annual bleeding rate ≥1 were significantly more willing to consider or accept gene therapy, suggesting that ongoing bleed burden shifts the perceived risk–benefit balance.
Together with the earlier Italian survey, these data show that patient acceptance of gene therapy cannot be taken for granted, even in high-income countries, and underline the need for clear, balanced, and culturally adapted education to support truly shared decision-making in haemophilia care.
Many thanks to the co-authors and to all participating patients, whose time and openness made this study possible.”
Title: An analysis of attitudes toward gene therapy in people with severe hemophilia in Germany, a survey-based cross-sectional study
Authors: Svetlana Babayeva, Aida Peyvandi, Christian Schepperle, Günter Auerswald, Steffen Rauchfuss, Flora Peyvandi, Ilaria Cutica, Wolfgang Miesbach
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 1, 2026, 18:51Francesco Giurazza: New Publication on Glubran-2 in Acute Bleeding Patients with Coagulopathies
-
Jun 1, 2026, 18:50Donald Arnold is the Recipient of the Roberts Award – ISTH
-
Jun 1, 2026, 18:49Amirreza Jabbaripour Sarmadian: My First Paper as Corresponding Author on Upper Extremity DVT Following COVID-19 Vaccination
-
Jun 1, 2026, 18:49James P. Crowley: How Combining Vitamin D analogs with Chemotherapy Impacts Survival Outcomes
-
Jun 1, 2026, 18:42Debojyoti Chakraborty: Small But Meaningful Steps Toward A Gene Editing Trial For Sickle Cell Disease In India
-
Jun 1, 2026, 17:14Tiffany Gacel: What an Incredible Day With NBCA and The Red Bus Tour at Memorial at Gulfport?
-
Jun 1, 2026, 17:12Marie-Claire Kofi: Poster Highlights the Process of Establishing the Sickle Cell Transitions Policy Lab
-
Jun 1, 2026, 17:00Azusa Nagao: Organizing the Symposium on Women and Bleeding Disorders at JSTH Annual Meeting
-
Jun 1, 2026, 16:57Kuljeet Kaur: Approach to Anemia – More Than Just a Low Hemoglobin